Biomerics Expands Manufacturing Operations In Texas

Biomerics, the leading vertically integrated medical device contract manufacturer in the interventional device market, announced the completion of a 24,000 sq. ft. expansion of manufacturing operations at their Athens, TX, facility. Driven by growth in the single-use endoscopy market, this investment includes 8,500 sq. ft. of production space and the expansion of Biomerics’ Center of Excellence for Balloons & Balloon Catheters with a 4,900 sq. ft. engineering laboratory adjacent to a CNC-machining (computer numerical control machining) tool shop.

“This expansion reflects our 30-year pursuit of innovation and manufacturing excellence. I’m thrilled to see our vertical integration on full display in one building,” stated Chris Richardson, President of Biomerics Interventional Advanced Catheter. “Our Center of Excellence for Balloons & Balloon Catheters in Athens has a long history of producing class-leading interventional products for our customers. The expansion will fuel our growth with best-in-class speed-to-market capabilities.”

The expansion increases the Athens campus to approximately 100,000 sq. ft. and includes an exterior refresh, additional engineering and lab space, manufacturing space and an employee break room. The Biomerics balloons and Interventional Advanced Catheter business operates out of three locations: Athens, TX; Brooklyn Park, MN; and Cartago, Costa Rica. Biomerics will celebrate the completion of the new campus expansion with a ribbon-cutting event today.

“The new building expansion in Athens Industrial Park is such a great demonstration of our partnership with Biomerics. They are a great corporate citizen and one of our largest employers. We are excited about the increase in investment, new jobs and what the future holds,” stated Joanie Ahlers, Director of Athens Economic Development Corporation.

“I am thrilled Biomerics continues to expand and reinvest in Athens,” Mayor Toni Clay said. “Here in Athens, we have some of the best talent in the nation. This makes our city and state a perfect fit for innovative companies like Biomerics. I look forward to seeing the continued growth and furthering our partnership for many years to come.”

“This investment says a lot about the performance of this team, our markets and our commitment to this community,” commented Travis Sessions, Chief Executive Officer of Biomerics. “We appreciate the support of the local community, state leaders and our many supply partners.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.